| 000 | 01395 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250511153724.0 | ||
| 264 | 0 | _c19770630 | |
| 008 | 197706s 0 0 eng d | ||
| 022 | _a0009-9236 | ||
| 024 | 7 |
_a10.1002/cpt1977215602 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRamsay, L | |
| 245 | 0 | 0 |
_aSpironolactone and canrenoate-K: relative potency at steady state. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cMay 1977 |
||
| 300 |
_a602-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCanrenoic Acid _xadministration & dosage |
| 650 | 0 | 4 |
_aCanrenone _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aFludrocortisone _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPotassium _xurine |
| 650 | 0 | 4 |
_aPregnadienes _xpharmacology |
| 650 | 0 | 4 |
_aSodium _xurine |
| 650 | 0 | 4 | _aSolutions |
| 650 | 0 | 4 |
_aSpironolactone _xadministration & dosage |
| 650 | 0 | 4 | _aTablets |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aAsbury, M | |
| 700 | 1 | _aShelton, J | |
| 700 | 1 | _aHarrison, I | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 21 _gno. 5 _gp. 602-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt1977215602 _zAvailable from publisher's website |
| 999 |
_c865779 _d865779 |
||